Welcome to our dedicated page for Sensus Healthcare SEC filings (Ticker: SRTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sensus Healthcare, Inc. (Nasdaq: SRTS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed medical device manufacturer focused on superficial radiotherapy (SRT and IG-SRT) for skin cancer and keloids, Sensus uses these filings to report material events, financial results and governance changes.
Recent Form 8-K filings describe quarterly financial results, where Sensus discusses revenue, unit shipments of SRT systems, Fair Deal Agreement treatment volumes, and the use of non-GAAP metrics such as Adjusted EBITDA. Other 8-Ks outline board developments, including the appointment of independent directors and related committee assignments, with the company noting compliance with Nasdaq independence standards.
Through its SEC reports, Sensus Healthcare also furnishes earnings press releases that include reconciliations between GAAP and non-GAAP financial measures, along with commentary on reimbursement milestones. For example, the company has highlighted the establishment of dedicated CPT codes by the Centers for Medicare & Medicaid Services for superficial radiotherapy used in non-melanoma skin cancer, which it views as important to its commercial strategy.
On Stock Titan, AI-powered tools can help readers interpret these filings by summarizing complex sections, highlighting key figures and pointing out notable changes from prior periods. Users can quickly identify items related to results of operations, board appointments, and other material events, and use the filings archive to follow how Sensus Healthcare’s financial profile and corporate governance have developed over time.
Sensus Healthcare, Inc. (SRTS)130,613 shares of Sensus Healthcare common stock directly, reflecting personal holdings. In addition, the filing reports 2,093 shares of common stock held indirectly through the insider's spouse. The form is filed by a single reporting person and indicates the insider's status as a director of the company, with no derivative securities reported.
Sensus Healthcare, Inc. (SRTS) reported an insider stock purchase by its Chief Executive Officer and director, Joseph C. Sardano. On 11/18/2025, he acquired 25,000 shares of Sensus Healthcare common stock in an open-market purchase transaction coded "P" at an average price of $4.03 per share, as noted in the explanation that this figure represents the average price per share.
Following this transaction, Sardano beneficially owns 1,200,293 shares of Sensus Healthcare common stock in direct ownership. The filing is made on Form 4 as a report by one reporting person in his capacity as both director and Chief Executive Officer of the company.
Sensus Healthcare, Inc. (SRTS)11/18/2025, he acquired 1,000 shares of common stock at a price of $3.80 per share, coded as a purchase transaction. Following this trade, he now beneficially owns 118,839 shares of Sensus Healthcare common stock with direct ownership.
Sardano is listed as a Director and as an Officer with the title President and General Counsel, indicating both governance and executive responsibilities at the company. This filing is made on Form 4, which reports changes in ownership of the company’s equity securities by insiders.
Sensus Healthcare, Inc. insider Michael Sardano, who serves as President, General Counsel, and a director of the company, reported open-market purchases of SRTS common stock. On 11/11/2025, he bought 1,000 shares of common stock at a price of $4.26 per share, bringing his directly owned holdings to 117,839 shares.
On the same date, his spouse purchased 766 shares at $4.27 per share and 234 shares at $4.34 per share, for a total of 1,000 shares held in the spouse’s name. The filing notes that Sardano disclaims beneficial ownership of the shares held by his spouse.
Sensus Healthcare appointed Eric Sachetta as a Class II director, filling the vacancy created by the passing of William McCall. His term runs until the 2026 annual meeting. The Board determined he is an independent director under Nasdaq Rule 5605(a)(2), and he has been named to the Audit Committee.
Sachetta is Chief Wealth Services Officer of Sachetta, LLC and a Certified Financial Planner. He will receive the same pro rata compensation as other non‑employee directors. The company reported no arrangements or transactions requiring disclosure under Item 404(a).
Sensus Healthcare (SRTS) officer and director Michael Sardano reported open‑market purchases on November 11, 2025.
He acquired 1,000 shares of common stock at $4.26 held directly. Additional purchases were reported for his spouse of 766 shares at $4.27 and 234 shares at $4.24. Following these transactions, Sardano held 117,839 shares directly. He disclaims beneficial ownership of his spouse’s shares. Sardano serves as President and General Counsel and is also a Director.
Sensus Healthcare (SRTS) reported Q3 2025 results showing softer demand and margin pressure. Revenue was $6.9 million, down 21.6% year over year, with gross profit of $2.7 million and a gross margin of 39.1% versus 59.1% a year ago. The quarter recorded a net loss of $0.9 million compared to net income of $1.2 million last year, driven by fewer unit sales and costs tied to a new placement program.
Operating expenses rose as the company increased R&D, marketing, and professional fees. Cash and cash equivalents were $24.5 million as of September 30, 2025, with accounts receivable at $9.3 million and inventories at $13.0 million. One U.S. customer accounted for 59% of quarterly revenue and 86% of accounts receivable. The company’s $15 million revolving credit facility had no borrowings outstanding; on September 26, 2025, the lender waived a default related to a minimum profitability covenant. Shares outstanding were 16,425,036 as of November 5, 2025.
Sensus Healthcare (SRTS) reported an insider stock purchase on Form 4. President and General Counsel, and Director, Michael Sardano bought 1,000 shares of common stock on 11/11/2025 at $4.26 per share.
Following the transaction, he beneficially owned 117,839 shares, held directly. This filing reflects routine insider activity and updates Sardano’s reported ownership position.
Sensus Healthcare, Inc. filed a current report to note that it issued a press release announcing its financial results for the quarter ended September 30, 2025. The company furnished this release as Exhibit 99.1 and incorporated it by reference. The press release includes certain non‑GAAP financial measures, along with reconciliations to the most directly comparable GAAP figures. The information provided under this earnings disclosure section, including Exhibit 99.1, is furnished rather than filed, which affects how it is treated under securities law.
Sensus Healthcare, Inc. completed a Form S-8 registration related to an employee benefit plan, filing corporate governance provisions including indemnification and the company’s ability to purchase insurance for directors and officers. The filing confirms that directors and officers may be indemnified for expenses, including attorneys’ fees, when successful in defense of covered actions, and that such indemnification is in addition to other rights under bylaws or agreements. Signatures from executive officers, including Joseph C. Sardano (Chief Executive Officer) and Javier Rampolla (Principal Financial and Accounting Officer), appear on the document.